Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with Polycystic Ovary Syndrome

Brief description of study

OCPs increase the risk of MetS specifically by producing an atherogenic lipoprotein phenotype, increasing blood pressure and/ or body weight while metformin modestly decreases MetS risk by decreasing body weight and improving lipid phenotype. The combination of OCP and metformin (OCP, through lowering androgens, and metformin, through improvement in insulin sensitivity) will likely decrease the prevalence of MetS, thereby altering the risk profile for the development of diabetes and possible cardiovascular disease (CVD) in young women with PCOS.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    polycystic ovary syndrome, PCOS, obese, overweight,
  • Age: Between 18 Years - 40 Years
  • Gender: Female


Updated on 05 Sep 2023. Study ID: 827819

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center